Other Operating Income

Other operating income was comprised as follows:

Other Operating Income

 

 

2017

 

2018

 

 

€ million

 

€ million

Gains on retirements of noncurrent assets

 

173

 

4,310

Reversal of impairment losses on receivables

 

23

 

184

Reversals of unutilized provisions

 

26

 

12

Gains from derivatives

 

291

 

217

Miscellaneous operating income

 

351

 

334

Total

 

864

 

5,057

Gains on retirements of noncurrent assets included proceeds of €4.1 billion from the sale of certain Crop Science businesses to BASF in connection with the acquisition of Monsanto (Crop Science segment). Furthermore, the divestment of several noncore brands at Consumer Health resulted in a gain of €49 million. The sale of a property in Berlin resulted in a gain of €41 million (Pharmaceuticals segment). The sale of the U.S. prescription dermatology business to LEO Pharma A/S, Ballerup, Denmark, generated a further gain of €25 million (Consumer Health segment).

Income from the reversal of impairment losses on receivables primarily resulted from the reversal of impairment losses under IFRS 9 and from improved receivables management in Brazil.

Within miscellaneous operating income, the proportionate assumption of costs by Janssen Research & Development, LLC, United States, a subsidiary of Johnson & Johnson, in connection with a development collaboration resulted in income of €189 million (Pharmaceuticals segment).

In the previous year, gains on retirements of noncurrent assets included a gain of €81 million from the sale of trademark rights (Consumer Health segment). Furthermore, the sale of capitalized transfer rights by Bayer 04 Leverkusen Fußball GmbH, Germany, resulted in a gain of €49 million (All Other Segments).

Compare to Last Year